Basic Information
Hexacima
Regulatory Information
EMEA/H/C/002702
April 17, 2013
February 21, 2013
32
June 11, 2024
Company Information
France
82 Avenue Raspail 94250 Gentilly
SANOFI WINTHROP INDUSTRIE
Active Substances Detail
hepatitis B surface antigenDiphtheria toxoidtetanus toxoidBordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutininpoliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett)Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Hexacima (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The use of this vaccine should be in accordance with official recommendations.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Hexacima. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Hexacima. For practical information about using Hexacima, patients should read the package leaflet or contact their doctor or pharmacist.